Investment firms Sofinnova Partners successfully closes its latest flagship fund, Sofinnova Capital XI, with €650 million to back a new generation of pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs Medicxi successfully closes its sixth fund, Medicxi V, with €500 million dedicated to building and backing innovative biotechnology companies with clear product […]